A subcutaneously administered RNAi therapeutic (ALN-AT3) targeting antithrombin for treatment of hemophilia: Interim phase 1 study results in healthy volunteers and patients with hemophilia a or B

Authors
Category Primary study
JournalBlood
Year 2014
This article has no abstract
Epistemonikos ID: 11d3eadac835e838e3da6ff98c09e6db0bd4f499
First added on: Feb 06, 2025